Condition
Progressive Multiple Sclerosis
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 38 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
38 shownA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10
RECRUITINGBringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) PatientsNCT07392879 · 2025-12-15
RECRUITINGObe-cel in Refractory Progressive Forms of Multiple SclerosisNCT07139743 · 2025-08-04
RECRUITINGEffects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple SclerosisNCT05811013 · 2023-05-27
RECRUITINGNicotinamide Riboside Supplementation In Progressive Multiple SclerosisNCT05740722 · 2023-05-03
RECRUITINGRESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisNCT07006805 · 2026-06-01
WITHDRAWNOpen-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)NCT06675864 · 2024-12-12
ACTIVE_NOT_RECRUITINGABA-101 in Participants With Progressive Multiple SclerosisNCT06566261 · 2024-09-11
ACTIVE_NOT_RECRUITINGTelerehabilitation in Progressive Multiple SclerosisNCT06485115 · 2024-06-30
UNKNOWNA Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisNCT06451159 · 2024-06-20
ACTIVE_NOT_RECRUITINGStudy of Circadian Focused Light Therapy in Progressive Multiple SclerosisNCT06261528 · 2024-04-18
ENROLLING_BY_INVITATIONOsmotin Plant Protein for Progressive Multiple SclerosisNCT05937802 · 2023-01-02
UNKNOWNMasitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisNCT05441488 · 2022-06-28
SUSPENDEDVisual Processing Speed and Objective Analysis of Ocular Movements in Multiple SclerosisNCT05706220 · 2022-06-13
ENROLLING_BY_INVITATIONMultiple Sclerosis Prediction and Monitoring of Progression StudyNCT05685784 · 2022-03-01
UNKNOWNStudy of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple SclerosisNCT04749667 · 2021-08-09
ACTIVE_NOT_RECRUITINGChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple SclerosisNCT04695080 · 2021-06-25
ACTIVE_NOT_RECRUITINGEffect of Variance on Error Correction During CouplingNCT04856384 · 2021-02-01
COMPLETEDIdentification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)NCT04289909 · 2020-12-01
COMPLETEDSerum Neurofilaments and GFAP in Atypical Multiple SclerosisNCT04201470 · 2019-12-09
COMPLETEDEfficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple SclerosisNCT04120675 · 2018-11-09
COMPLETEDA Trial of Bile Acid Supplementation in Patients With Multiple SclerosisNCT03423121 · 2018-06-19
COMPLETEDComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisNCT03493841 · 2018-06-08
COMPLETEDEvaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple SclerosisNCT03552211 · 2018-05-30
UNKNOWNNeural Stem Cell Transplantation in Multiple Sclerosis PatientsNCT03269071 · 2017-05-17
COMPLETEDG-EO Gait Rehabilitation Training in Progressive Multiple SclerosisNCT03980145 · 2017-05-02
COMPLETEDA Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisNCT02977533 · 2016-12-01
COMPLETEDA Study of Oxidative Pathways in MS FatigueNCT02804594 · 2016-10-01
COMPLETEDStudy to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple SclerosisNCT03302806 · 2016-06-29
COMPLETEDA Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple SclerosisNCT02583594 · 2015-12-06
COMPLETEDAccess, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.NCT02559765 · 2015-08-01
COMPLETEDA Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668NCT02313285 · 2015-01-12
COMPLETEDA First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisNCT02282826 · 2014-10-01
COMPLETEDStudy by Magnetic Resonance Imaging in the Progressive Forms of Multiple SclerosisNCT02580669 · 2014-06-16
TERMINATEDAssessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)NCT01815632 · 2014-01-01
UNKNOWNCyclic Oral Methylprednisolone Trial in Multiple SclerosisNCT01305837 · 2011-04-01
COMPLETEDSafety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaNCT01364246 · 2010-01-01
UNKNOWNIntrathecal Therapy With Monoclonal Antibodies in Progressive Multiple SclerosisNCT01719159 · 2009-11-01
COMPLETEDCommon interventions
PlaceboDRUG6AcyclovirDRUG3GZ402668DRUG2methylprednisoloneDRUG2ABA-101BIOLOGICAL1Adaptive Optics Ophthalmoscopy (AOO)OTHER1alemtuzumab GZ402673DRUG1Alpha Lipoic AcidDRUG1biotinDRUG1Blood withdrawalOTHER1Bytelfies kit - sensor dotDEVICE1CABA-201BIOLOGICAL1CeterizineDRUG1Chemotherapy: cyclophosphamide (CYC)DRUG1Chemotherapy: fludarabine (FLU)DRUG1Cladribine (MAVENCLAD®)DRUG1Conventional Physical TherapyOTHER1Conventional therapyOTHER1DexchlorpheniramineDRUG1Digital Telerehabilitation (Euleria Home)DEVICE1Early Harvest Extra Virgin Olive OilDIETARY_SUPPLEMENT1Early infusion of autologous marrowOTHER1Eye trackingDIAGNOSTIC_TEST1G-EO System (Reha Technology AG: Olten, Switzerland)DEVICE1human fetal-derived Neural Stem Cells (hNSCs)DRUG1
Leading sponsors
Genzyme, a Sanofi Company
3
Haukeland University Hospital
2
University Hospital, Montpellier
2
AB Science
1
Abata Therapeutics
1
Anders Svenningsson
1
Aristotle University Of Thessaloniki
1
Autolus Limited
1
Bruce Cree
1
Cabaletta Bio
1
Copenhagen University Hospital, Rigshospitalet
1
Hasselt University
1
Hoffmann-La Roche
1
Indiana University
1
Institut National de la Santé Et de la Recherche Médicale, France
1
Trial status mix
COMPLETED17
UNKNOWN6
ACTIVE_NOT_RECRUITING5
RECRUITING5
ENROLLING_BY_INVITATION2
SUSPENDED1
TERMINATED1
WITHDRAWN1
Phase mix
PHASE114
PHASE212
NA11
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.